ClinicalTrials.Veeva

Menu

Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

J

Jordan Leitch

Status and phase

Begins enrollment this month
Phase 4

Conditions

Cesarian Section
Cardiac Ischemia

Treatments

Drug: Carbetocin

Study type

Interventional

Funder types

NETWORK

Identifiers

Details and patient eligibility

About

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.

  • Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases?
  • Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section.

Participants will:

  • Be given 50mcg or 100mcg of carbetocin during cesarian section
  • Asked to report cardiac symptoms
  • Be assessed for ECG changes and blood loss using standard of practice monitoring
  • Have a troponin I blood test completed after delivery

Enrollment

200 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Undergoing elective cesarian section
  • Primary and repeat cesarian section

Exclusion criteria

  • Prior and current cardiovascular co-morbidities including pre-eclampsia
  • BMI greater than 50
  • Pre-existing bleeding disorders
  • Allergy to carbetocin
  • Age under 18

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

200 participants in 2 patient groups

50mcg of Carbetocin
Experimental group
Description:
Participants in this arm will receive 50mcg of carbetocin for post party hemorrhage prophylaxis at the the time of umbilical cord clamping during their cesarian section.
Treatment:
Drug: Carbetocin
100mcg of Carbetocin
Active Comparator group
Description:
Participants in this arm will receive 100mcg of carbetocin for post party hemorrhage prophylaxis at the the time of umbilical cord clamping during their cesarian section.
Treatment:
Drug: Carbetocin

Trial contacts and locations

1

Loading...

Central trial contact

Taylor Perry, MD; Jordan Leitch, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems